Pricing Log in Create free account
Friday 6 November 2026 Export ALNY’s income statement to Excel — free account

Alnylam Pharmaceuticals, Inc.

ALNY Healthcare Biotechnology

Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.

Revenue
+16.7%
EPS
+747.6%
Free cash flow
−4.76%
Total debt
−2.66%

Quarter to September 2026, against a year earlier

157.11 0.45 +0.29%
Market cap
$21.0B
P/E
7.9×
Fwd P/E
13.5×
Dividend yield
—
F-score
6/9
Altman Z
7.30
Beneish M
−1.95
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Alnylam Pharmaceuticals, Inc. (ALNY) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Alnylam Pharmaceuticals, Inc. (ALNY) trades at a EV/Sales of 3.7×. Over the past ten years it has ranged from 3.7× (November 2026) to 201× (August 2016) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 9.0× and in line with the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 13.6× 8.15%
FY2024 12.6× 0.61%
FY2023 12.5× (52.25%)
FY2022 26.3× 21.01%
FY2021 21.7× (19.33%)
FY2020 26.9× (47.78%)
FY2019 51.5× (38.53%)
FY2018 83.8× (26.67%)
FY2017 114× 90.46%
FY2016 60.0× (63.86%)

Quarterly newest first

Period EV/Sales Change
Sep 2026 6.1× (23.06%)
Jun 2026 7.9× (19.37%)
Mar 2026 9.8× (28.26%)
Dec 2025 13.6× (24.80%)
43 more quarters

Against its own ten years

Low 3.7× High 201×
Ten-year median 36.3×
Current reading's percentile 0

EV/Sales against peers

Company EV/Sales
BNTX BioNTech SE Sponsored ADR compare 1.8×
INCY Incyte Corporation compare 3.4×
ALNY Alnylam Pharmaceuticals, Inc. 3.7×
JAZZ Jazz Pharmaceuticals PLC compare 3.7×
EXEL Exelixis, Inc. compare 6.5×
ASND Ascendis Pharma A/S compare 13.1×
INSM Insmed, Inc. compare 15.4×
BBIO BridgeBio Pharma, Inc. compare 15.9×
ROIV Roivant Sciences Ltd. compare 3,061×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on ALNY